Lannett Company, Inc. Signs Exclusive Contract Manufacturing Agreement With Wintac Limited; Expands Pipeline With New Dosage Forms

PHILADELPHIA--(BUSINESS WIRE)--Jan. 17, 2006--Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced the signing of an exclusive, multi-product contract manufacturing agreement with Wintac Limited, an Indian pharmaceutical company, based in Bangalore. Under the terms of the agreement, Lannett will market in the U.S. certain pharmaceutical ophthalmic and parenteral products produced by Wintac. Lannett will assemble and submit to the FDA Abbreviated New Drug Applications (ANDAs) for the products covered in the agreement from data provided by Wintac.

MORE ON THIS TOPIC